



Magyar Gyógyszerésztudományi Társaság Congressus Pharmaceuticus Hungaricus XVI.

Debrecen, Kőlcsey Központ 2020. április 23-25.



Dr. Greiner István, kutatási igazgató

Richter Gedeon Nyrt.

New chemical entity R&D at a CEE midpharma company (From here to eternity)

Új kémiai anyagok kutatása és fejlesztése egy közép-kelet-európai gyógyszergyárban (innen az örökkévalóságig)

As the cost of new chemical and/or biological entity R&D is continuously increasing, reaching 1.5-2.5 billion USD, its feasibility in case of a midpharma company is getting to be more and more questionable. At the same time it is even more challenging in the CEE environment where both the financial and the human resources are much more limited than in the developed countries. Notwithstanding the aforesaid four years ago a compound invented and co-developed in Hungary has got marketing authorization in the US, the biggest market of pharma products on the world. The success is ongoing, now its sales reached nearly half billion last year and can jump up to 1 billion USD peak sales according some analysts. During my lecture a short story of cariprazine R&D and in connection with it the related challenges we are facing here will be presented. While I have no crystal ball to show the future only my ideas and thoughts will be shared with the participants about the possible way out from this labyrinth and reach success on this very difficult field of innovation.